Barclays analyst Luke Sergott raised the firm’s price target on Avantor (AVTR) to $26 from $25 and keeps an Overweight rating on the shares. The firm says the life science tools group will likely continue to work overall on the last estimate cut thesis and Q1 guides “coming in very conservative” that makes it hard to see companies missing targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR: